select ad.sno,ad.journal,ad.title,ad.author_names,ad.abstract,ad.abstractlink,j.j_name,vi.* from articles_data ad left join journals j on j.journal=ad.journal left join vol_issues vi on vi.issue_id_en=ad.issue_id where ad.sno_en='92593' and ad.lang_id='3' and j.lang_id='3' and vi.lang_id='3' Prevalence and Treatment for Alcohol Use Disorders Based on | 92593
Журнал алкоголизма и наркотической зависимости

Журнал алкоголизма и наркотической зависимости
Открытый доступ

ISSN: 2329-6488

Абстрактный

Prevalence and Treatment for Alcohol Use Disorders Based on Kentucky Medicaid 2012-2019 Datasets

Huirong Hu, Riten Mitra, Yuchen Han, Subhadip Pal, Haojing Huang, Craig McClain, Vatsalya Vatsalya, K.B. Kulasekera, Maiying Kong*

Alcohol use is the leading substance use in the United States. Persons with alcohol use disorder (AUD) face enormous health consequences and family problems. Analysis of Medicaid enrollee data is critical to understand different aspects of AUD and the treatment utilization for patients with AUD. Yearly patient-level data were constructed from the Kentucky 2012-2019 Medicaid claims data. ICD-9-CM and ICD-10-CM codes were used to identify patients with AUD and their comorbid conditions, the 11-digit National Drug Codes were used to identify medication treatments, and procedure codes were used to identify psychosocial and behavioral therapies. Logistic regression models were used to examine factors that were associated with AUD treatments. The prevalence of AUD trended up over time. Patients living in metro areas, between ages 45-54, having mental disorders, tobacco use, and with a family history of alcoholism had significantly higher rates of AUD. About 60% of patients diagnosed with AUD had major depressive disorder or anxiety. The treatment utilization for AUD also trended up from 2012 to 2019; however, it was still lower than 25% in 2019. Pharmacological treatments were used in only 2.89% of cases in 2012, which increased to 8.13% in 2019. Psychosocial treatments were used in only 1.59% of cases in 2012 that increased to 18.95% in 2019. The prevalence of AUD trended up over years. However, the treatment utilization for AUD was lower than 25%, even as of 2019. There is an urgent need for comprehensive, evidence-based, personalized AUD treatments.

Отказ от ответственности: Этот тезис был переведен с использованием инструментов искусственного интеллекта и еще не прошел рецензирование или проверку.
Top